Which placebo to cure depression? A thought-provoking network meta-analysis. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles BMC Medicine Year : 2013

Which placebo to cure depression? A thought-provoking network meta-analysis.


BACKGROUND: Antidepressants are often considered to be mere placebos despite the fact that meta-analyses are able to rank them. It follows that it should also be possible to rank different placebos, which are all made of sucrose. To explore this issue, which is rather more epistemological than clinical, we designed an unusual meta-analysis to investigate whether the effects of placebo in one situation are different from the effects of placebo in another situation. METHODS: Published and unpublished studies were searched for by three reviewers on Medline, the Cochrane Library, Embase, clinicaltrials.gov, Current Controlled Trial, in bibliographies, and by mailing key organizations. The following studies in first-line treatment for major depressive disorder were considered to construct an "evidence network": 1) randomized controlled trials (RCTs) versus placebo on fluoxetine, venlafaxine and 2) fluoxetine versus venlafaxine head-to-head RCTs.Two network meta-analyses were run to indirectly compare response and remission rates among three different placebos: 1) fluoxetine placebo, 2) venlafaxine placebo, and 3) venlafaxine/fluoxetine placebo (that is, placebo compared to both venlafaxine and fluoxetine). Publication biases were assessed using funnel plots and statistically tested. RESULTS: The three placebos were not significantly different in terms of response or remission. The antidepressant agents were significantly more efficacious than the placebos, and venlafaxine was more efficacious than fluoxetine. The funnel plots, however, showed a major publication bias. CONCLUSION: The presence of significant levels of publication bias indicates that we cannot even be certain of the conclusion that sucrose equals sucrose in trials of major depressive disorder. This result should remind clinicians to step back to take a more objective view when interpreting a scientific result. It is of crucial importance for their practice, far more so than ranking antidepressant efficacy.
Fichier principal
Vignette du fichier
1741-7015-11-230.pdf (632.03 Ko) Télécharger le fichier
1741-7015-11-230-S1.DOC (168 Ko) Télécharger le fichier
1741-7015-11-230.xml (83.93 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Format : Other

Dates and versions

inserm-00879846 , version 1 (05-11-2013)



Florian Naudet, Bruno Millet, Philippe Charlier, Jean Michel Reymann, Anne Solène Maria, et al.. Which placebo to cure depression? A thought-provoking network meta-analysis.. BMC Medicine, 2013, 11 (1), pp.230. ⟨10.1186/1741-7015-11-230⟩. ⟨inserm-00879846⟩
418 View
377 Download



Gmail Facebook X LinkedIn More